seqonomics.blogspot.com
Seqonomics: April 2014
http://seqonomics.blogspot.com/2014_04_01_archive.html
On making genomics useful. Thursday, 3 April 2014. How useful is genomics for drug discovery? In a previous post. I discussed a number of large sequencing projects, including by the governments of Saudi Arabia. And the United Kingdom. Which are sequencing the genomes of 100,000 of their citizens each. Three recent developments stand out:. A large biopharmarmaceutical company, has teamed up with Geisinger Health Systems. A local American healthcare network, to sequence 100,000 exomes. Overall, it seems th...
blog.opentargets.org
Target Validation API Tutorial: Getting Started
https://blog.opentargets.org/api-getting-started-1
Target Validation API Tutorial: Getting Started. Since release 1.1 the Target Validation Platform exposes a public REST API. To allow programmatic retrieval of data served at targetvalidation.org. This is the same API that powers our website and gives full access to the data used to build www.targetvalidation.org. The Available methods are divided in to:. Methods that serve the core set of our data and that we will keep stable and support. Methods to get statistics and technical data about the API. Curl ...
grch37.ensembl.org
Acknowledgements
http://grch37.ensembl.org/info/about/credits.html
Geek for a Week. Browser Genome Release Agreement. Ensembl name and logo policy. Credits for species images. About the Ensembl Project. Co-funded by the European Union. Previous sources of funding. EU Framework Programme 6. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n 282510 - BLUEPRINT. The small icons used in the web interface are derived from the Rocky set by Icon Dock. View in current Ensembl.
opentargets.org
Projects | Open Targets
http://www.opentargets.org/projects
Skip to main content. Core Bioinformatics and Data Pipelines. We leverage the power of our partners’ data analyses and annotation to integrate information about common and rare diseases. Our work on core components and pipelines forms the backbone of information and display for the Open Targets Platform, and encompasses any type of data that is relevant to human disease biology. Open Targets has developed state-of-the-art analysis methods for its immunology focus, which includes inflammatory bowel diseas...
opentargets.org
People | Open Targets
http://www.opentargets.org/people
Skip to main content. Open Targets brings our partners together, integrating their expertise through open collaborative research and engagement events. Site maintained by the Web Development team at.
opentargets.org
News | Open Targets
http://www.opentargets.org/news
Skip to main content. Monday, 27 February, 2017. Open Targets - First Impressions. I recently joined the Open Targets Consortium as Operations Director. This moved me from almost the very end of the R&D pipeline where I had been working on processes for small molecule therapies to the very beginning stages of drug discovery, where we find and prioritise targets. To read David's post please visit : https:/ blog.opentargets.org/open-targets-first-impressions/. Monday, 12 December, 2016. The starting point ...
opentargets.org
Jobs | Open Targets
http://www.opentargets.org/jobs
Skip to main content. Postdoctoral Fellow - neurobiology and bioinformatics. Hemberg Group, WTSI. View the position details. Closing date: Thursday, 23 March, 2017. ChEMBL team, EMBL-EBI. View the position details. Closing date: Thursday, 9 March, 2017. Senior/Advanced Research Assistant - Immune Genomics. Gosia Trynka's Group, WTSI. Collaboration between GlaxoSmithKline, Biogen, EMBL-EBI (European Bioinformatics Institute) and the Wellcome Trust Sanger Institute (WTSI), where the goal is to use genome-s...
blogs.bbsrc.ac.uk
national capabilities | BBSRC Chief Executive's blog
http://blogs.bbsrc.ac.uk/index.php/tag/national-capabilities
Site navigation ↓. News, events and publications. A week in California. Realising the promise of the bioeconomy. Recently we in BBSRC have been thinking more holistically about our research and translational activities with a focus on the bioeconomy as it relates to our portfolio. Over the past few years a number of countries (for example, Germany (PDF). Plant and animal health research reviewing progress and scoping the future. I also got a sneak preview of the 100,000 genomes building.
SOCIAL ENGAGEMENT